ModernGraham Valuation

Company Name:

Company Ticker LLY Date of Analysis Eli Lilly And Co





Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$81,906,882,355	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	1.32	Fail
3.	Earnings Stability	Positive EPS for 10 years prior		Fail
4.	Dividend Record	Dividend Payments for 10 years prior		Pass
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	-43.40%	Fail
6.	Moderate PEmg Ratio	PEmg < 20	30.37	Fail
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	6.73	Fail
Enterprising Investor; mus	t pass 4 out of the following 5 tests, or be s	uitable for the Defensive Investor.		

1.	Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.32	Fail
2.	Sufficiently Strong Financial Condition	Debt to NCA < 1.1	2.13	Fail
3.	Earnings Stability	Positive EPS for 5 years prior		Fail
4.	Dividend Record	Currently Pays Dividend		Pass
5.	Earnings Growth	EPSmg greater than 5 years ago		Fail
		Score		

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

		\$2.46
vth Estimate		-4.25%
e		\$0.00
e based on 3% Growth		\$35.70
e based on 0% Growth		\$20.93
nplied Growth Rate		10.93%
Price		\$74.76
nsic Value	N/A	
	Overvalued	
le	D	
	e e based on 3% Growth e based on 0% Growth nplied Growth Rate Price nsic Value	e based on 3% Growth e based on 0% Growth nplied Growth Rate Price nsic Value N/A Overvalued


Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$13.59
Graham Number	\$33.17
PEmg	30.37
Current Ratio	1.32
PB Ratio	6.73
Current Dividend	\$2.08
Dividend Yield	2.78%
Number of Consecutive Years of Dividend Growth	3

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate		Next Fiscal Year Estimate	\$2.46
Dec2017	-\$0.19	Dec2017	\$1.66
Dec2016	\$2.58	Dec2016	\$2.73
Dec2015	\$2.26	Dec2015	\$2.96
Dec2014	\$2.23	Dec2014	\$3.45
Dec2013	\$4.32	Dec2013	\$4.07
Dec2012	\$3.66	Dec2012	\$3.58
Dec2011	\$3.90	Dec2011	\$3.24
Dec2010	\$4.58	Dec2010	\$2.72
Dec2009	\$3.94	Dec2009	\$1.80
Dec2008	-\$1.89	Dec2008	\$0.93
Dec2007	\$2.71	Dec2007	\$2.30
Dec2006	\$2.45	Dec2006	\$2.11
Dec2005	\$1.81	Dec2005	\$2.02
Dec2004	\$1.66	Dec2004	\$2.21
Dec2003	\$2.37	Dec2003	\$2.50
Dec2002	\$2.50	Dec2002	\$2.52
Dec2001	\$2.55	Balance Sheet Information	12/1/2017
Dec2000	\$2.79	Total Current Assets	\$19,202,100,000
Dec1999	\$2.46	Total Current Liabilities	\$14,535,900,000
Dec1998	\$1.87	Long-Term Debt	\$9,940,500,000
		Total Assets	\$44,981,000,000
		Intangible Assets	\$8,399,300,000
		Total Liabilities	\$33,388,800,000
		Shares Outstanding (Diluted Average)	1,043,692,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other	47 Companies in the Spotlight This Week - 5/16/15
ModernGraham posts about the	Eli Lilly & Co. Annual Valuation – 2015 \$LLY
company	58 Companies in the Spotlight This Week - 1/31/15
	Eli Lilly & Company Quarterly Valuation – January 2015 \$LLY
	<u>18 Companies in the Spotlight This Week – 10/25/14</u>
Other	Zoetis Inc Valuation – March 2018 \$ZTS
ModernGraham posts about related	Gilead Sciences Inc Valuation – March 2018 \$GILD
companies	Pfizer Inc Valuation – February 2018 \$PFE
	Merck & Co Inc Valuation – February 2018 \$MRK
	Johnson & Johnson Valuation – February 2018 \$JNJ
	Bristol-Myers Squibb Co Valuation – September 2017 \$BMY
	Momenta Pharmaceuticals Inc Valuation - Initial Coverage \$MNTA
	Depomed Inc Valuation – Initial Coverage \$DEPO
	Endo International PLC Valuation – July 2017 \$ENDP

Biogen Inc Valuation - July 2017 \$BIIB